Showing results (111-120 of 176) with videos related to
Sort By:
Pageof 18
Oncotarget|December 15, 2015
Efficacy and toxicity of bevacizumab in recurrent ovarian disease: an update meta-analysis on phase III trialsClaudia Marchetti, Francesca De Felice, Innocenza Palaia, et al.Annals of Surgical Oncology|September 29, 2016
Effects of Neoadjuvant Chemotherapy Plus Radical Surgery as Front Line Treatment Strategy in Patients Affected by FIGO Stage III Cervical CancerViolante Di Donato, Michele Carlo Schiavi, Ilary Ruscito, et al.Oncology|October 12, 2011
Use of adjuvant therapy in patients with FIGO stage III endometrial carcinoma: a multicenter retrospective studyClaudia Marchetti, Carmela Pisano, Giorgia Mangili, et al.European Journal of Cancer (Oxford, England : 1990)|June 23, 2026
Hold the line: Local control strategies in oligoprogressive gynecologic cancers during systemic therapyFilippo Casaccia Giordano, Roberta Lazzari, Gabriella Macchia, et al.Expert Opinion on Investigational Drugs|March 8, 2016
Ixabepilone for the treatment of endometrial cancerClaudia Marchetti, Ilaria Piacenti, Ludovica Imperiale, et al.Journal of Cellular and Molecular Medicine|September 29, 2009
Ovarian cancer cytoreduction induces changes in T cell population subsets reducing immunosuppressionChiara Napoletano, Filippo Bellati, Rachele Landi, et al.Oncology|September 26, 2017
Short-Infusion Trabectedin in Heavily Pretreated Ovarian Cancer Patients: A Single-Institution ExperienceClaudia Marchetti, Angela Musella, Alessia Romito, et al.Oncotargets and Therapy|July 18, 2014
Targeted drug delivery via folate receptors in recurrent ovarian cancer: a reviewClaudia Marchetti, Innocenza Palaia, Margherita Giorgini, et al.International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 8, 2026
Olaparib dose reduction in BRCA-mutated platinum-sensitive ovarian cancer recurrence: real-world dataSerena Maria Boccia, Matteo Bruno, Camilla Culcasi, et al.Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|January 13, 2016
Cediranib in ovarian cancer: state of the art and future perspectivesIlary Ruscito, Maria Luisa Gasparri, Claudia Marchetti, et al.Pageof 18